Answers are grounded in this paper and cite their sources.
Population-based cohort study shows low LDL-C correlates with higher all-cause and cardiovascular mortality in cancer survivors, indicating risks vary by age and cardiovascular history.
Objectives To evaluate the association between LDL-C levels and all-cause, cardiovascular, and cancer mortality in cancer survivors, and to identify the LDL-C level associated with the lowest mortality risk, using data from NHANES 1999–2018. Study design Population-based cohort study. Methods We analyzed 1,958 U.S. cancer survivors from the National Health and Nutrition Examination Survey (NHANES) 1999–2018. We used Cox and Fine-Gray model to compare mortality risks across LDL-C quartiles, combined with restricted cubic spline analysis to assess nonlinear relationships, and piecewise linear regression to identify LDL-C inflection points. Results During a median follow-up of 7.3 years (681 deaths were recorded), we observed a nonlinear association between LDL-C levels and all-cause/cardiovascular mortality, wherein low levels of LDL-C were associated with an increased mortality risk. The identified optimal LDL-C thresholds were 119 mg/dl for all-cause mortality and 124 mg/dl for cardiovascular mortality. Age and CVD history influenced the association, with a negative linear relationship between LDL-C and all-cause mortality observed in individuals aged under 65 years and those in the primary CVD prevention. Conclusions Cancer survivors with low LDL-C levels were correlated with elevated all-cause and CVD mortality risks, particularly in younger patients and those without prior CVD.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: